Vertex Pharmaceuticals (VRTX) Profit After Tax (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Profit After Tax for 18 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 59.59% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.3 billion (up 538.7% YoY), while the FY2025 annual figure was $4.0 billion, up 838.09% from the prior year.
• Profit After Tax came in at $1.0 billion for Q1 2026 at Vertex Pharmaceuticals, down from $1.2 billion in the prior quarter.
• The five-year high for Profit After Tax was $1.2 billion in Q4 2025, with the low at -$3.6 billion in Q2 2024.
• Average Profit After Tax over 5 years is $670.0 million, with a median of $930.5 million recorded in 2022.
• Across the five-year window, Profit After Tax jumped 1109.7% in 2022 and plunged 492.44% in 2024, its largest moves.
• Year by year, Profit After Tax stood at $818.9 million in 2022, then advanced by 18.31% to $968.8 million in 2023, then declined by 5.76% to $913.0 million in 2024, then jumped by 30.46% to $1.2 billion in 2025, then slipped by 13.41% to $1.0 billion in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $1.0 billion, $1.2 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.